PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.89%
Negative net income growth indicates shrinking profitability. Benjamin Graham would label it a concern unless explained by temporary factors.
6.88%
D&A 5-10% yoy – Noticeable rise. Peter Lynch would hope new assets produce higher revenue to offset the expense.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Negative yoy SBC growth reduces new equity issuance. Benjamin Graham would verify that enough talent investment remains for growth.
-183.61%
A negative yoy change in working capital can free up cash. Benjamin Graham would confirm it is not from falling demand or asset disposal.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-219.11%
A negative yoy AP change means the firm is paying down supplier credit. Benjamin Graham would see it as lowering short-term liabilities if revenue is stable.
200.00%
Above 30% yoy – Major jump. Philip Fisher would demand details on these miscellaneous lines to ensure transparency.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Negative yoy CFO growth indicates a decline in core cash generation. Benjamin Graham would treat it as a serious warning unless cyclical factors explain it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
33.33%
Debt repayment growth above 20% yoy – Strong deleveraging. Warren Buffett would see improved balance sheet health unless expansions are starved.
-53.76%
A negative yoy figure could mean fewer or no new shares or even net buybacks. Benjamin Graham would see it as positive unless expansions need capital that internal cash cannot provide.
No Data
No Data available this quarter, please select a different quarter.